Gossamer Bio CEO Faheem Hasnain at #BIO22 (J.T. MacMillan Photography)
Gossamer lays off 25% of employees, cuts all programs except PAH drug
As Gossamer Bio goes all in on its lead drug for pulmonary arterial hypertension (PAH), it’s cutting off all other clinical and preclinical programs — as well as 25% of its staff.
Faheem Hasnain, the co-founder, CEO and chair of Gossamer, called the restructuring decision difficult in a press release but “a necessary step to focus the organization on activities which maximize the potential of seralutinib,” the PAH candidate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
